Cargando…

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

BACKGROUND AND AIMS: There are increasing case reports of rhino-orbital mucormycosis in people with coronavirus disease 2019 (COVID-19), especially from India. Diabetes mellitus (DM) is an independent risk factor for both severe COVID-19 and mucormycosis. We aim to conduct a systematic review of lit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh Kumar, Singh, Ritu, Joshi, Shashank R., Misra, Anoop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Diabetes India. Published by Elsevier Ltd. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137376/ https://www.ncbi.nlm.nih.gov/pubmed/34192610 http://dx.doi.org/10.1016/j.dsx.2021.05.019

Ejemplares similares

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comments on: Rise of the phoenix: Mucormycosis in COVID-19 times
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

COVID-19 associated mucormycosis: A Descriptive Multisite Study from India
por: Gupta, Ritesh, et al.
Publicado: (2021)

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19()
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
por: Nassar, Mahmoud, et al.
Publicado: (2023)

Absence of Case of Mucormycosis (March 2020–May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit
por: Mulakavalupil, Bindu, et al.
Publicado: (2021)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Clinical considerations for patients with diabetes in times of COVID-19 epidemic
por: Gupta, Ritesh, et al.
Publicado: (2020)

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

A systematic review of mucormycosis cases in COVID-19: Is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids?
por: Kumar, Rajesh, et al.
Publicado: (2022)

Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Letter to the editor in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)”
por: Kumar Singh, Awadhesh, et al.
Publicado: (2020)

COVID-19: From bench to bed side
por: Singh, Akriti, et al.
Publicado: (2020)

COVID-19-associated mucormycosis: Case report and systematic review
por: Dilek, Ahmet, et al.
Publicado: (2021)

Mucormycosis and COVID-19: Double trouble for India?
por: Yasmin, Farah, et al.
Publicado: (2022)

Investigation of an acute surge of COVID-19 associated mucormycosis (CAM) cases reported to a tertiary health care institution in Bihar, India
por: Singh, Chandra Mani, et al.
Publicado: (2022)

Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature
por: Garg, Deepak, et al.
Publicado: (2021)

The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2022)

A case control investigation of COVID-19 associated mucormycosis in India
por: Anand, Tanu, et al.
Publicado: (2022)

Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Letter in response to letter to the editor by Singh and Dhibar regarding the article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Akriti, et al.
Publicado: (2020)

Mucormycosis in COVID-19 Patients: A Case-Control Study
por: Pandit, Awadh Kishor, et al.
Publicado: (2022)

COVID-19 Associated Mucormycosis
por: Tazeem, Sana, et al.
Publicado: (2023)

Is Mucormycosis an inevitable complication of Covid-19 in India?
por: Bhogireddy, Ramadevi, et al.
Publicado: (2021)

COVID-19-Associated Mucormycosis in a Tertiary Care Hospital in India: A Case Series
por: Singh, Shivam, et al.
Publicado: (2022)

Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India
por: Muthu, Valliappan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vi1fj26tu4p3mnh6bbjdf4h53e